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Background
Previously, we demonstrated that protein kinase G type-Ia
(PKG-Ia) plays an important role in promoting cell survi-
val in neural cells (N1E-115 neuroblastoma and NG108-
15 neuroblastoma-glioma hybrid cells) and significantly
contributes to the serine-155 phosphorylation of BAD, an
apoptosis-regulating protein [1]. We also found that PKG-
Ia promotes cell survival and proliferation in mouse OP9
bone marrow stromal cells [2] and human ovarian cancer
cells [3] [determined by using both pharmacological inhi-
bitors (ODQ, DT-2 and DT-3) and gene knockdown
(siRNA) to reduce PKG-Ia/b activity]. In the case of ovar-
ian cancer cells, which predominantly express the PKG-Ia
isoform, the pro-growth and pro-survival effects involved
a novel interaction between PKG-Ia and the oncogenic
protein c-Src [3]. For example, intracellular activation of
PKG-Ia, assessed by VASP serine-239 phosphorylation,
was dependent on c-Src-catalyzed tyrosine phosphoryla-
tion of PKG-Ia (i.e. VASP phosphorylation was blocked
by Src inhibitors, SKI-1 or SU6656) and the intracellular
activation of c-Src was (somehow) dependent on the
kinase activity and expression levels of PKG-Ia (i.e. c-Src
activation was decreased by DT-2 or siRNA-induced
knockdown of PKG-Ia).
Hypothesis, research plan and methods
We hypothesize that c-Src activation in cancer cells
involves the PKG-Ia-catalyzed phosphorylation of a
serine or threonine residue of c-Src, likely serine-17
(because amino acid residues around the serine-17 site of
c-Src provide a good consensus sequence for PKG-Ia/b).
The present study determines: 1) if PKG-Ia/b can
directly phosphorylate c-Src at serine-17 using in vitro
conditions, 2) if serine-17-phophorylation of c-Src, in
intact cancer cells, is dependent on PKG-Ia/b expression
and kinase activity (using pharmacological inhibitors and
shRNA gene knockdown), and 3) if the same inhibition/
knockdown of PKG-Ia/b alters cell survival, proliferation
and attachment. Objectives # 2 and 3 were tested in a
non-small cell lung cancer (NSCLC) cell line, NCI-H23,
and two mesothelioma cell lines, MSTO-211H and NCI-
H2052. The serine-17 phosphorylation of c-Src was
determined by Western blot analysis using an antibody
(developed in collaboration with Cell Signaling Technol-
ogies) that is specific for the phosphorylated-serine-17
site of c-Src. Protein expression of PKG-Ia and PKG-Ib
was determined by both conventional Western blot ana-
lysis and a new ultrasensitive, highly-quantitative capil-
lary-electrophoresis-based immuno-quantification
system, the NanoPro100 system (Cell Biosciences, Inc.,
Santa Clara, CA, USA). The NanoPro100 system allows
clear separation and identification of the different PKG-I
isoforms and phosphorylated forms.
Results
In in vitro incubations using recombinant human c-Src
and either PKG-Ia or PKG-Ib, both recombinant PKG-Ia
and PKG-Ib were able to directly catalyze the phosphory-
lation of serine-17 in c-Src, resulting in increased autopho-
sphorylation of c-Src at tyrosine-419 (equivalent to
tyrosine-416 in mouse c-Src). The NSCLC cells (NCI-H23
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isoform, whereas both of the mesothelioma cell lines
(MSTO-211H and NCI-H2052) express both PKG-Ia and
PKG-Ib. In all cell lines, inhibition of PKG-Ia/b kinase
activity using DT-2 or silencing of PKG-Ia/b expression
using shRNA dramatically reduced the intracellular phos-
phorylation of c-Src at serine-17, whereas addition of the
PKG activator 8-bromo-cGMP increased c-Src phosphory-
lation at serine-17. Both the kinase-activity inhibition and
knockdown of PKG-Ia/b caused significant increases in
apoptosis (i.e. decreases in cell survival) and dramatically
decreased the cell proliferation, colony formation and cell
attachment in both the lung cancer and mesothelioma
cells.
Conclusion
The mesothelioma cells in this study express both PKG-
Ia and PKG-Ib, and the inhibition of their expression or
kinase activity results in dramatic suppression of the
phosphorylation of c-Src at serine-17 and the endogen-
ous activation of c-Src as well as the cell survival, prolif-
eration and attachment of these cells. Because the kinase
inhibitors and shRNA constructs are (at present) not able
to discriminate between the two PKG-I isoforms, it is not
yet possible to identify which PKG-I isoform is mediating
the c-Src phosphorylation and the pro-survival, pro-
growth and pro-attachment effects of PKG-I in mesothe-
lioma cells. In the NCI-H23 lung cancer cells, which
express only the PKG-Ia isoform, the PKG-Ia was identi-
fied as a key protein kinase mediating the enhanced
phosphorylation and activation of c-Src and the down-
stream enhancement of cell survival (contributing to che-
moresistance), proliferation and attachment of these lung
cancer cells. This builds upon our previous observation
that c-Src kinase activity promotes tyrosine-phosphoryla-
tion and activation of PKG-Ia in ovarian cancer cells.
Thus, it appears that the interactions between c-Src and
PKG-I in cancer cells may represent a novel “oncogenic
re-enforcement”, with each protein kinase phosphorylat-
ing and enhancing the kinase activity of the other, ulti-
mately contributing to chemoresistance and tumor
growth. This interaction between c-Src and PKG-I may
provide a novel target for the development of new anti-
cancer therapeutic agents.
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